Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | CCR4 | P51679 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780235 | 0.81 | CCR4 (0.44) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13780279 | 0.81 | CCR4 (0.44) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4208839 | 0.79 | PDE4A (0.41) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13780220 | 0.79 | HRH4 (0.43) | HRH4HRH1HTR3ACCR4HTR2A | |
| SCHEMBL13780228 | 0.78 | CCR4 (0.41) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4204698 | 0.77 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL16258707 | 0.76 | CCR4 (0.55) | CCR4 | |
| SCHEMBL16258705 | 0.75 | CCR4 (0.67) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL13780238 | 0.74 | CCR4 (0.53) | PDE4APDE4BPDE4CPDE4DHRH4 | |
| SCHEMBL4211641 | 0.74 | HRH4 (0.43) | PDE4APDE4BPDE4CPDE4DHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | HTR2C 564/4885PDE4A 600/4885PDE4B 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.